Engitix Therapeutics raised $54 million in Series A financing. Engitix plans to use the money to boost the company’s drug discovery pipeline in fibrosis and cancer and expand its team, facilities and operations.
If you are not happy with the results below please do another search
50 search results for:
When used in children, rapid antigen tests for detecting the coronavirus do not meet accuracy criteria set by the World Health Organization and U.S. and UK device regulators, according to researchers who reviewed 17 studies of the tests. Other research appears to confirm smaller, earlier studies that suggested nursing mothers are unlikely to transmit the coronavirus in breastmilk.
Ceptur Therapeutics – based in Hillsborough, NJ, Philadelphia and Copenhagen – closed on a Series A financing round worth $75 million.
Valneva said on January 19 that preliminary studies showed three doses of the French biotech firm’s inactivated COVID-19 vaccine candidate neutralized the Omicron variant of the disease.
The U.S. government will make 400 million non-surgical N95 masks from its strategic national stockpile available for free to the public starting next week, a White House official said, marking the Biden administration’s latest effort to help curb the COVID-19 pandemic.
ImmunityBio shared interim results from the company’s ongoing metastatic pancreatic cancer trial, demonstrating overall survival that is double the historical rate.
COVID-19 infections are reaching new peaks in the Americas with 7.2 million new cases and more than 15,000 COVID-related deaths in the last week, the Pan American Health Organization (PAHO) said on January 19.
Pfizer released data from several studies showing that nirmatrelvir, the active main protease inhibitor of the company’s antiviral combination therapy Paxlovid (nirmatrelvir/ritonavir), is effective against the Omicron variant of SARS-CoV-2. Additionally, a study conducted by 23andMe and published in Nature Genetics identified a genetic risk factor tied to the loss of smell from COVID-19.
AstraZeneca reported what the company called “unprecedented survival,” in the HIMALAYA Phase III trial using a single priming dose of tremelimumab added to the anti-PD-L1 checkpoint inhibitor Imfinzi (durvalumab) compared to Bayer’s Nexavar (sorafenib) as a first-line treatment for unresectable hepatocellular carcinoma (HCC) patients who had not received previous systemic therapy and as a result, were not eligible for localized treatment.
Hal Barron, who guided the reinvigoration of the pharmaceutical direction at GlaxoSmithKline, is departing the company as GSK undergoes a planned demerger later during 2022.